company logo

Team Lead Biostatistics in Boston, MA

Save

compensation:

$80K - $100K*

specialty:

Life Sciences

experience:

5 - 7 years

Job Description

To advance the development of Tafasitamab and in preparation for its planned commercialization MorphoSys founded MorphoSys US Inc., a wholly owned subsidiary of MorphoSys AG, and raised independent funding by successfully closing an IPO on the Nasdaq U.S. stock exchange in April 2018. Our focused, controlled growth and commercialization journey has been substantial starting in 2018 with our US IPO and culminating in our Incyte Corporation partnership in 2020. These three years have been important for MorphoSys as we continue to strive to deliver innovative medicines to patients who need them. The company is realizing our goal of becoming a fully integrated global biopharmaceutical company.

Tafasitamab is an investigational, Fc-engineered therapeutic antibody targeting CD19 that is in development for the treatment of B cell malignancies. The focus of the development program is on relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), a particularly aggressi

See More

Valid through: 2020-5-20

About MorphoSys AG

Total Jobs:
13
Average Pay:
$171,560
Total value of jobs:
$21,445,000
% Masters:
100%
Learn More About MorphoSys AG
* Ladders Estimates